SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
The trial’s objectives are to evaluate the safety, tolerability and efficacy of SciSparc’s SCI-210 in…
Month: August 2022
Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022
Live conference call on Friday, August 12 at 8:30 a.m. EST MIAMI, Aug. 08, 2022…
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later…
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company…
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call…
Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development
Extends Rani’s projected cash runway into mid-2024 SAN JOSE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE)…
RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or…
TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as…
Vaxart Appoints W. Mark Watson to its Board of Directors
Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif.,…
Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology…
Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344
BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or…
Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical and Distribution Partner Marathon Medical Awarded Contract to Provide SAMI Dialysis Devices to the US Department of Veterans Affairs
TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:…
Impel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) — Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical…
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical…
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Conference call to be held today, August 8, 2022 at 8:30 AM ET NEW YORK,…
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
New York, NY, and Tel Aviv, ISRAEL, Aug. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos…
CinCor Reports Second Quarter Financial Results and Provides Corporate Update
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant…
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the…
CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in…